Clinical Trial

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Study acronym: ZEST
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.
Protocol Amendment History 1 change
notable Trial sites expanded: 5 -> 9 locations 2026-05-27
Trial Details
NCT Number NCT07237516
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: Celltrion
Conditions Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
Enrollment 200 participants
Start Date 2025-11-20
Primary Completion 2028-11-03 (estimated)
Study Completion 2028-11-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-05